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Abstract 
BACKGROUND: The Fourth Universal Definition of Myocardial Infarction defines electrocardiographic (ECG) 
Q waves as duration ≥30ms and amplitude ≥1mm or QS complex in two contiguous leads. However, current 
taskforce criteria may be overly restrictive. Therefore, we investigated the association of isolated, lenient, or 
strict Q waves with long-term outcome. 
 
METHODS: From 2001–2015, we included Danish primary care patients with digital ECGs that were 
evaluated for Q waves. If none occurred, patients had no Q waves. If no other contiguous Q wave occurred, 
patients had isolated Q waves. If another contiguous Q wave occurred meeting only one criterion (≥30ms 
and <1mm or <30ms and ≥1mm), patients had lenient Q waves. If another contiguous Q wave occurred, 
patients had strict Q waves. 
 
RESULTS: Of 365,206 patients, 87,957 had isolated, lenient, or strict Q waves (24%; median age, 61 years; 
male, 48%), and 277,249 had no Q waves (76%; median age, 53 years; male, 42%). Mortality risk was 
increased with isolated (all-cause adjusted hazard ratio [aHR], 1.33; 95% confidence interval [CI], 1.29–1.37; 
cardiovascular-cause aHR, 1.78; 95% CI, 1.70–1.87), lenient (all-cause aHR, 1.41; 95% CI, 1.33–1.50; 
cardiovascular-cause aHR, 1.78; 95% CI, 1.63–1.94), or strict (all-cause aHR, 1.64; 95% CI, 1.57–1.72; 
cardiovascular-cause aHR, 2.70; 95% CI, 2.52–2.89) Q waves compared with no Q waves. Highest mortality 
risk was associated with anteroseptal lenient or strict Q waves. 
 
CONCLUSIONS: This large contemporary analysis suggests that less stringent Q-wave criteria carry 
prognostic value in predicting adverse outcome among primary care patients. 
 
KEYWORDS: Electrocardiogram; Fourth Universal Definition of Myocardial Infarction; Myocardial infarction; 
Primary care; Q wave; Epidemiology. 
Clinical Significance 
 Among primary care patients with digital electrocardiograms, any Q wave whether isolated, lenient, 
or strict was associated with increased long-term mortality risk compared with no Q waves. 
 These findings may help in reclassifying patients currently considered at low cardiovascular risk to a 
different risk category where additional testing and medical intervention could be necessary. 
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Introduction 
Q waves on the electrocardiogram (ECG) are highly suggestive of prior or silent and potentially unrecognized 
myocardial infarction and are associated with larger infarct size as assessed on cardiac magnetic resonance 
imaging (MRI).1, 2 Detection of Q waves is clinically important as their emergence carry prognostic value of 
future cardiovascular disease burden.3-7 
Over the years, various Q-wave criteria have emerged, with the most recent recommended in the 2018 
consensus document the Fourth Universal Definition of Myocardial Infarction8 (Table 1). From a 
cardiovascular risk stratification standpoint, strict Q waves (duration ≥30 ms and amplitude ≥1 mm or QS 
complex in two contiguous leads), as defined by current taskforce criteria, may be overly restrictive, 
particularly among patients with cardiovascular risk factors or subclinical cardiovascular disease. In contrast, 
isolated Q waves, where Q waves in a contiguous lead are absent, may represent an incidental finding and 
be of limited prognostic value.3 However, to date, no real-world evidence is available on the clinical 
importance of lenient Q waves meeting only one criterion (duration ≥30 ms and amplitude <1 mm or 
duration <30 ms and amplitude ≥1 mm). 
The clinical approach to patients with Q waves raising the suspicion of prior or silent and potentially 
unrecognized myocardial infarction is to do imaging studies with echocardiogram or cardiac MRI to 
determine whether myocardial infarction occurred or not. However, in primary care, such additional testing 
is not accessible without specialist referral, and delayed access to outpatient care and potentially delayed 
initiation of cardiovascular preventive interventions may worsen outcomes. Therefore, detecting less 
stringent Q-wave criteria in primary care may be beneficial in early cardiovascular risk stratification and 
referral purposes. 
Using a large contemporary clinical database including nearly 1 million digital ECGs from primary care 
patients from the greater Copenhagen area in Denmark, we investigated the mortality risk associated with 
isolated, lenient, or strict Q waves using current taskforce criteria. 
Methods 
Study Design and Population 
This was a Danish register-based cohort study including the most recent available ECG from primary care 
patients referred to the central core facility Copenhagen General Practitioners’ Laboratory from 2001 to 
2015.9, 10 All 12-lead ECGs were recorded at rest and in supine position, digitally stored in the MUSE 
Cardiology Information System, and processed and automatically scored using the Marquette 12SL algorithm 
(GE Healthcare, Chicago, IL, USA).11 Trained ECG technicians have manually described all ECGs that further 
have been over read by a consultant cardiologist. Data on age and sex were obtained from the Danish Civil 
Registration System12 and vital status from the Danish Register of Causes of Death.13 
Patients with missing demographic data were excluded, so were those <16 years, as the 12SL algorithm 
applies pediatric as opposed to adult criteria in this group. Patients were also excluded if they were 
erroneously registered with a death date prior to ECG recording. Furthermore, using 12SL algorithm 
statements, we excluded ECGs of poor quality, with pacemaker rhythms, and not qualified for suitable Q-
wave interpretation, mainly applying to ECG abnormalities causing axis deviation, as incidental Q waves may 
occur.14 This included bradycardia or tachycardia (heart rate <50 or >120 beats per min, respectively), 
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Sokolow-Lyon or Cornell voltage criteria for left ventricular hypertrophy, atrial fibrillation, junctional rhythm, 
retrograde conduction, second- or third-degree atrioventricular block, premature atrial or ventricular 
complexes, ventricular rhythms, fascicular or bundle branch blocks, and delta waves. 
 
Q-Wave Subtypes 
In accordance with current task force criteria, Q waves were defined in any two leads of a contiguous lead 
grouping: inferior (II with aVF), (III with aVF), and (aVF with II or III); anteroseptal (V1 with V2), (V2 with V1 or 
V3), (V3 with V2 or V4), and (V4 with V3 or V5); and anterolateral (V5 with V4 or V6), (V6 with V5), (I with 
aVL), and (aVL with I). 
Using 12SL algorithm measurements, ECGs were evaluated for Q waves (duration ≥30 ms and amplitude 
≥1 mm or QS complex [Q amplitude >0 mm and R amplitude = 0 mm]) in each of the leads II, III, aVF, V1–V6, 
I, and aVL. If none occurred, patients had no Q waves (Figure 1A). If no other Q wave occurred in a 
contiguous lead, patients had isolated Q waves (Figure 1B). If another Q wave occurred in a contiguous lead 
meeting only one criterion (duration ≥30 ms and amplitude <1 mm or duration <30 ms and amplitude ≥1 
mm), patients had lenient Q waves (Figure 1C). If another Q wave occurred in a contiguous lead, patients 
had strict Q waves (Figure 1D). Of note, patients may demonstrate more than one Q-wave subtype, thus the 
total of isolated, lenient, and strict Q waves sums to >100%. 
 
Comorbidities, Procedures, and Cardiovascular Drugs 
To further exclude ECGs with potential pacemaker rhythms, we used the Danish National Patient Register15 
to identify patients with a prior pacemaker or implantable cardioverter-defibrillator using International 
Classification of Diseases (ICD) and Nordic Classification of Surgical Procedures (NCSP) codes, whichever 
came first. Furthermore, we used ICD codes in the Danish National Patient Register to identify heart failure, 
myocardial infarction, atrial fibrillation, valvular heart disease, hypertension, diabetes, chronic obstructive 
pulmonary disease, and chronic kidney disease diagnosed prior to ECG recording. We also used NCSP codes 
to identify percutaneous coronary intervention for myocardial infarction, radiofrequency ablation for atrial 
fibrillation, aortic or mitral valve surgery for valvular heart disease, and renal replacement therapy for 
chronic kidney disease. 
Using Anatomical Therapeutic Chemical (ATC) codes in the Danish National Prescription Register,16 filled 
prescriptions of cardiovascular drugs were identified within 180 days prior to ECG recording. Usually, 
hypertension, diabetes, and chronic obstructive pulmonary disease are managed in primary care, and 
patients may not necessarily have ICD codes registered. Therefore, prior filled prescriptions of 
antihypertensives (at least dual therapy), antidiabetics, and beta adrenergic or anticholinergic inhalants were 
further used to define these comorbidities, respectively.17 See Supplementary Table 1 (available online) for 
ICD, NCSP, and ATC codes. 
 
Outcome Measure 
The ECG recording represented the baseline of our study. The main outcome was all-cause mortality, and we 
performed an additional analysis using death from any cardiovascular cause (ICD-8, 400–451; ICD-10, I00–
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99). Patients were followed for up to 2 years until outcome or censoring in case of emigration, end of follow-
up, or end of study on December 31, 2017, whichever came first. 
 
Statistical Analysis 
Continuous variables were reported as medians with 25th–75th percentiles and categorical variables as 
counts with percentages. Differences were compared using Mann-Whitney U and chi-squared tests, as 
appropriate. 
Cumulative incidence of mortality for no, isolated, lenient, or strict Q waves was computed and displayed 
using the Kaplan-Meier method. Cox regression was used to compute hazard ratios (HRs) with 95% 
confidence intervals (CIs) for mortality risk associated with isolated, lenient, or strict Q waves, with no Q 
waves as reference. The proportional hazard assumption was tested by plotting cumulative Martingale 
residuals and was not violated. Interaction testing was based on introducing an interaction term in a Cox 
regression model and using a likelihood ratio test to compare this model with one without an interaction 
term. A two-sided P-value <0.01 was considered statistically significant for interactions and <0.05 for all 
other analyses. Linearity of continuous variables was also assessed using a likelihood ratio test comparing a 
linear description with a categorical one. Age was observed to violate linearity and was included as a 
categorical variable based on quartiles. Analyses were adjusted for age quartiles, sex, heart failure, 
myocardial infarction, atrial fibrillation, valvular heart disease, hypertension, lipid-lowering drugs, diabetes, 
chronic obstructive pulmonary disease, and chronic kidney disease. 
Data management and analysis were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and R, version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). 
 
Ethics 
The Danish Data Protection Agency approved use of data (reference: 2007-58-0015, internal reference: GEH-





We included 365,206 patients, of which 87,957 (24%) had isolated, lenient, or strict Q waves, and 277,249 
(76%) had no Q waves (Supplementary Figure 1, available online). Patients with isolated, lenient, or strict Q 
waves were older (median age, 61 years) and more often male (48%) than patients with no Q waves (median 
age, 53 years; male, 42%). Patients with isolated, lenient, or strict Q waves also demonstrated higher 
comorbidity burden and more often filled cardiovascular drug prescriptions. Although statistically significant, 
no clinical differences in ECG characteristics were observed between groups (Table 2). 
Among the 87,957 patients with isolated, lenient, or strict Q waves, 74,726 patients (85%) had isolated Q 
waves localized in inferior (n=44,047; 59%), anteroseptal (n=22,875; 31%), and anterolateral (n=13,908; 19%) 
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leads. A total of 14,373 patients (16%) had lenient Q waves localized in inferior (n=11,259; 78%), 
anteroseptal (n=853, 6%), and anterolateral (n=2579, 18%) leads. Finally, 17,165 patients (20%) had strict Q 
waves localized in inferior (n=10,142; 59%), anteroseptal (n=7015, 41%), and anterolateral (n=1487, 9%) 
leads (Supplementary Table 2, available online). Of note, 17,454 patients (20%) demonstrated more than 
one Q-wave subtype, of which 11,314 patients (65%) had isolated and lenient Q waves, 3081 patients (18%) 
had isolated and strict Q waves, 2206 patients (13%) had lenient and strict Q waves, and 853 patients (5%) 
had isolated, lenient, and strict Q waves. 
Mortality Risk by Q-Wave Subtypes 
During 2-year follow-up, a total of 8312 patients (10%) with isolated, lenient, or strict Q waves died from all 
causes compared with 12,664 patients (5%) with no Q waves (Figure 2). This was similar with cardiovascular 
mortality (n=3728, 4% vs n=4615, 2%). 
Following multivariable adjustment, mortality risk remained increased for isolated (all-cause HR, 1.33; 
95% CI, 1.29–1.37; cardiovascular-cause HR, 1.78; 95% CI, 1.70–1.87), lenient (all-cause HR, 1.41; 95% CI, 
1.33–1.50; cardiovascular-cause HR, 1.78; 95% CI, 1.63–1.94), or strict (all-cause HR, 1.64; 95% CI, 1.57–1.72; 
cardiovascular-cause HR, 2.70; 95% CI, 2.52–2.89) Q waves compared with no Q waves in any two leads of a 
contiguous lead grouping. We observed similar findings by inferior, anteroseptal, and anterolateral leads, 
with highest mortality risk associated with lenient (all-cause HR, 1.77; 95% CI, 1.51–2.08; cardiovascular-
cause HR, 2.66; 95% CI, 2.12–3.33) or strict (all-cause HR, 1.89; 95% CI, 1.78–2.00; cardiovascular-cause HR, 
3.12; 95% CI, 2.85–3.40) anteroseptal Q waves (Figure 3). 
 
Sensitivity Analyses 
We performed various sensitivity analyses to test the consistency and robustness of our findings. 
First, we investigated mortality risk in each of the leads II, III, aVF, V1–V6, I, and aVL, and while isolated Q 
waves in leads III, aVF, and V5 were of limited prognostic value, findings from remaining leads resembled the 
main analysis (Supplementary Figure 2, available online). 
Second, we tested whether age, sex, and prior myocardial infarction modified the association of isolated, 
lenient, or strict Q waves with all-cause mortality risk. No interactions were observed, and effect sizes were 
similar by subgroups (Supplementary Figure 3–5, available online). 
Third, although we accounted for ECG abnormalities and comorbidities commonly associated with axis 
deviation, residual axis deviation may potentially affect findings. Therefore, we performed an additional 
subgroup analysis of patients with normal axis between –30° and +90° (n=343,780; 94%), and mortality risk 
was more pronounced (Supplementary Figure 6, available online). 
Fourth, we observed that no additional prognostic value was gained when lenient Q waves were stratified 
by duration (≥30 ms and <1 mm) and amplitude (<30 ms and ≥1 mm) criteria (Supplementary Figure 7, 
available online). 
Fifth, according to current taskforce criteria, the likelihood of myocardial infarction is increased if ST-T 
deviations occur in the same leads as Q waves. We observed that mortality risk increased dramatically when 
criteria for ST depression, ST elevation, or inverted T waves were concomitantly present (Supplementary 
Figure 8, available online). 
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Discussion 
In this large-scale nationally representative study of real-word primary care patients, we report a series of 
key findings underscoring that additional prognostic value may be gained by considering less stringent Q-
wave criteria than those recommended in the Fourth Universal Definition of Myocardial Infarction. First, in 
any two leads of a contiguous lead grouping, we demonstrated that 16% of patients with lenient Q waves, of 
which 14% did not have concomitant strict Q waves, were potentially misclassified as not having excess 
cardiovascular risk according to current taskforce criteria. Second, we demonstrated similar prognostic value 
between lenient and strict Q waves, with nearly a 2-fold increased mortality risk in anteroseptal leads. 
Importantly, the prognostic value did not differ when lenient Q waves were stratified by duration and 
amplitude criteria. Third, although the majority of patients demonstrated isolated Q waves, these were 
associated with differential prognostic value. Fourth, all findings were consistent when excluding the few 
patients with residual axis deviation. Finally, we demonstrated that mortality risk increased by more than 2-
fold when ST-T deviations accompanied isolated, lenient, or strict Q waves, thus potentially reflecting higher 
coronary artery disease burden. 
The ECG plays a pivotal role in diagnosing and managing myocardial infarction owing to universal 
availability and low costs. However, if myocardial infarction is not timely diagnosed or silent and potentially 
unrecognized, the prognosis is poor, with increased risks of heart failure and mortality. While prior studies 
have investigated and debated the utility of isolated or strict Q waves,3-7 no contemporary studies have 
described whether additional prognostic value may be gained by considering lenient Q waves. Our novel 
findings can easily be integrated into current clinical practice and suggest that, in addition to strict Q waves, 
clinicians should be aware when observing lenient Q waves regardless of location. Of note, prior studies 
have reported a rather comparable prognosis between inferior and anterior Q waves.3, 6 Considering current 
clinical practice, we speculate that particularly patients with lenient Q waves are not recognized as 
candidates for imaging studies with echocardiogram or cardiac MRI to determine whether myocardial 
infarction occurred or not and for cardiovascular prevention interventions, thus they potentially have 
accelerated incidences of myocardial infarction and heart failure, with an associated increase in mortality 
risk over time. In support, a recent study suggests that patients with borderline Q waves, as defined 
according to the Minnesota Code, have an unfavorable cardiovascular risk profile potentially associated with 
adverse outcome.18 However, further work is warranted to explore the extent of subclinical myocardial 
injury, as detected by less stringent Q-wave criteria, and whether targeted cardiovascular drug therapies for 
myocardial infarction and heart failure including aspirin, statins, angiotensin-converting enzyme inhibitors, 
or beta blockers may improve prognosis in this group. It also remains unknown how patients with isolated, 
lenient, or strict Q waves differ regarding myocardial scar burden, structural and electrical remodeling, and 
left ventricular ejection fraction. 
It is beyond the scope of our study to conclude whether Q waves that are wide, deep, or both matters the 
most. In prior studies, Q waves ≥40 ms, as defined according to the Minnesota Code, have been observed to 
carry a poorer prognosis than Q waves defined according to less stringent Minnesota Code criteria and to 
carry a comparable prognosis to Q waves defined using the Fourth Universal Definition of Myocardial 
Infarction.3, 6 However, in a prior autopsy study, 90% of inferior myocardial infarction cases could be 
detected with a duration ≥30 ms rather than ≥40 ms in lead aVF.19 In another study, the amplitude rather 
than duration measured early following myocardial infarction was associated with infarct size on cardiac 
MRI, although this association reversed at follow-up where duration became more strongly associated with 
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infarct size.20 It has further been observed that a certain threshold of infarct size should be reached on 
cardiac MRI to detect significant Q waves.1, 2 
 
Limitations 
Our study has several limitations worth noting, particularly the observational design only allowing 
associations to be established, not causation. Furthermore, unmeasured and unknown confounding 
including cardiovascular symptoms, family history of cardiovascular disease, ethnicity, obesity, and smoking 
status may affect findings, but such data was unfortunately not available in our registers. However, obesity 
and smoking status were indirectly accounted for by adjusting analyses for hyperlipidemia and chronic 
obstructive pulmonary disease, respectively. Although we relied on the ECG to detect whether patients had 
prior or silent and potentially unrecognized myocardial infarction, echocardiography and cardiac MRI are 
more sensitive tools in detecting this condition, but we did unfortunately not have  such data available. 
Finally, we identified that around 3% of all patients had a diagnosis of prior myocardial infarction in the 
Danish National Patient Register, and the rather low prevalence may be attributed to various reasons 
including Q-wave regression or silent and potentially unrecognized myocardial infarction. However, the 
validity of the  diagnosis in the Danish National Patient Register has proven to be high.21 
 
Conclusions 
This large contemporary analysis suggests that lenient, strict, and, to a lesser extent, isolated Q waves carry 
prognostic value in predicting adverse long-term outcome among primary care patients. This finding has 
potential clinical implications for reclassifying patients currently considered at low cardiovascular risk to a 
different category where additional testing and medical intervention could be necessary, although further 
work is warranted to explore this. 
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Figure 1: Definitions and representative examples of no (A), isolated (B), lenient (C), or strict (D) Q waves.  
No Q waves identified
(A) No Q wave
(C) Lenient Q wave
No Q wave
At least 1 Q wave identified
In combination with the following
from a contiguous lead
• Q duration ≥30 ms
• Q amplitude <1 mm
• Q duration <30 ms
• Q amplitude ≥1 mm
or
(B) Isolated Q wave
Another Q wave
(D) Strict Q wave
Electrocardiographic Q-wave definition
based on initial evaluation of Q waves
• Q duration <30 ms
• Q amplitude <1 mm; and no
• QS complex: Q amplitude >0 mm
• QS complex: R amplitude = 0 mm
• Q duration ≥30 ms
• Q amplitude ≥1 mm; or
• QS complex: Q amplitude >0 mm
• QS complex: R amplitude = 0 mm
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Figure 2: Cumulative incidence of 2-year all-cause mortality for no, isolated, lenient, or strict Q waves by any 
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Figure 3: Association of isolated, lenient, or strict Q waves with 2-year all-cause (A) and cardiovascular (B) 
mortality risk compared with no Q waves by any two leads of a contiguous lead grouping, inferior, 
anteroseptal, and anterolateral leads. 
Adjusted for age quartiles, sex, heart failure, myocardial infarction, atrial fibrillation, valvular heart disease, 
hypertension, lipid-lowering drugs, diabetes, chronic obstructive pulmonary disease, and chronic kidney 
disease. 
Abbreviations: CI, confidence interval; HR, hazard ratio. 
 
Table 1: Q-Wave Criteria According to the Fourth Universal Definition of Myocardial Infarction.
8
 
Any Q wave in leads V2–V3 >20 ms or QS complex in leads V2–V3 
Q wave ≥30 ms and ≥1 mm or QS complex in leads I, II, aVL, aVF, 
or V4–V6 in any two leads of a contiguous lead grouping (I, aVL; 
V1–V6; II, III, aVF) 
R wave >40 ms in leads V1–V2 and R/S >1 with a concordant 
positive T wave 
 
Table 2: Patient Characteristics. 
 
Isolated, Lenient, or Strict Q Waves 
(n=87,957) 




Age, years 61.0 [48.0–73.0] 53.0 [40.0–66.0] <0.001 
0.5 1.0 1.5 2.0 2.5 3.0 3.50.5 1.0 1.5 2.0 2.5 3.0 3.5
Any lead
  No Q wave
  Isolated Q wave
  Lenient Q wave











Inferior leads (II, III, aVF)
  No Q wave
  Isolated Q wave
  Lenient Q wave










  No Q wave
  Isolated Q wave
  Lenient Q wave









Anterolateral leads (V5–V6, I, aVL)
  No Q wave
  Isolated Q wave
  Lenient Q wave












































         
Downloaded for Anonymous User (n/a) at Aalborg Hospital from ClinicalKey.com by Elsevier on October 28, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
14 
Sex (male) 41,770 (47.5) 115,973 (41.8) <0.001 
ECG characteristics 
Heart rate, bpm 71.0 [63.0–81.0] 69.0 [62.0–78.0] <0.001 
P-wave duration, ms 110.0 [102.0–118.0] 108.0 [100.0–116.0] <0.001 
PR interval, ms 162.0 [146.0–180.0] 154.0 [142.0–170.0] <0.001 
QRS duration, ms 90.0 [84.0–100.0] 90.0 [84.0–98.0] 0.025 
QT interval, ms 394.0 [374.0–414.0] 394.0 [376.0–414.0] <0.001 
Fridericia-corrected QT interval, ms 416.0 [403.0–430.0] 414.0 [402.0–427.0] <0.001 
Comorbidities 
Heart failure 3890 (4.4) 4200 (1.5) <0.001 
Myocardial infarction 6014 (6.8) 5511 (2.0) <0.001 
Atrial fibrillation 3112 (3.5) 6018 (2.2) <0.001 
Valvular heart disease 1129 (1.3) 1578 (0.6) <0.001 
Hypertension 18,417 (20.9) 33,512 (12.1) <0.001 
Diabetes 10,679 (12.1) 18,994 (6.9) <0.001 
Chronic obstructive pulmonary disease 10,555 (12.0) 24,869 (9.0) <0.001 
Chronic kidney disease 2134 (2.4) 4757 (1.7) <0.001 
Cardiovascular drugs 
Loop diuretics 6461 (7.3) 9607 (3.5) <0.001 
Thiazide diuretics 10,960 (12.5) 22,145 (8.0) <0.001 
ACEIs or ARBs 22,219 (25.3) 43,045 (15.5) <0.001 
Mineralocorticoid receptor antagonists 1373 (1.6) 1985 (0.7) <0.001 
Beta blockers 10,800 (12.3) 20,504 (7.4) <0.001 
Calcium channel blockers 12,587 (14.3) 24,421 (8.8) <0.001 
Antianginal drugs 2834 (3.2) 3755 (1.4) <0.001 
Antiplatelets 17,005 (19.3) 27,631 (10.0) <0.001 
Lipid-lowering drugs 16,889 (19.2) 31,922 (11.5) <0.001 
Values reported as median [25th–75th percentiles] or n (%). P Values based on Mann-Whitney U and chi-squared tests, as 
appropriate. 
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; bpm, beats per minute. 
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